RAGWITEK AMBROSIA ARTEMISIIFOLIA POLLEN 12 [Amb'a'1'U]/1 Tablet, Carton of 30 — NDC 52709-1601-03 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

NDC 52709-1601-03: RAGWITEK AMBROSIA ARTEMISIIFOLIA POLLEN 12 [Amb'a'1'U]/1 Tablet, Carton of 30

by ALK-Abello A S
Inner NDC 52709-1601-1 on each blister pack (10 tablets) inside this package 11-digit 52709-1601-01

This is a package of 30 tablets of RAGWITEK AMBROSIA ARTEMISIIFOLIA POLLEN 12 [Amb'a'1'U]/1 Tablet from ALK-Abello A S, no longer marketed (first marketed Apr 2014), no longer in the FDA NDC Directory; retail pharmacies pay about $11.75 per tablet (NADAC). It is the main listing for this product, which comes in 2 package sizes.

🏷️ FDA NDC (as labeled) 52709-1601-3 billing pads the package segment with a zero
This package
Contains30-count Cost per ea$11.75 NADAC Per package$352.47 / 30 tablets Pack sizes2 compare ↓
Also priced by: Medicaid pays $11.74/unit — full pricing hub ↓
Main listing for product 52709-1601 · Also comes in: 5 tablets 52709-1601-5
Brand Discontinued Non-controlled ⚠ Inactivated by FDA ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Aug 6, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 52709-1601-3 alone.

Record
FDA NDC Directory package listing · Standardized allergenic
Code segments
52709 labeler · 1601 product · 3 package
Package marketed since
Apr 17, 2014
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Billing quantity
30 EA per package
Barcode (UPC-A, from the NDC)
3 5270916013 5
Medicaid fills, this package
132 prescriptions in the last four reported quarters
FDA record last changed
Aug 6, 2026
⚠️
Excluded from the active FDA NDC Directory. FDA inactivated this product’s listing record, so it is excluded from the active NDC Directory. The listing was last certified through Dec 2027. A label may still appear on DailyMed, but the NDC is no longer in the current FDA NDC Directory. Search the FDA NDC Directory ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 52709-1601-3
Product NDC 52709-1601
11-digit billing NDC 52709160103
NCPDP billing unit EA — each (per item)
Application # BLA125478
SPL Set ID 70216cba-11b5-40fd-8656-9f27b24f7b60
Established class (EPC) Standardized Pollen Allergenic Extract
Physiologic effect Cell-mediated Immunity; Increased Histamine Release; Increased IgG Production
Chemical class Allergens; Pollen
DEA schedule Non-controlled
Marketing category BLA
Marketing status Discontinued
FDA listing status Inactivated by FDA (certified through Dec 2027)
Marketing start 2014-04-17
Route SUBLINGUAL
Dosage form TABLET
Substance AMBROSIA ARTEMISIIFOLIA POLLEN
Biologic (Purple Book) 351(a)

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 20100060200720
GPI class Ragwitek
GCN Seq No 072266
GCN 36402
HICL code 041079
Ingredient (HICL) Allergenic Extract-Weed Pollen-Short Ragweed
HIC1 code W
Therapeutic class — broad (HIC1) Anti-Infecting Agents
HIC2 code W7
Therapeutic class — intermediate (HIC2) Biologicals
HIC3 code W7W
Therapeutic class — specific (HIC3) Allergenic Extracts, Therapeutic
AHFS code 80:02.00.00
AHFS class Allergenic Extracts (Therapeutic)
FDB label name RAGWITEK SUBLINGUAL TABLET
FDB brand name Ragwitek
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 072266
  • GCN: 36402
  • GPI-14 (Medi-Span): 20100060200720
  • HICL (First Databank): 041079
  • AHFS class code: 80:02.00.00
Why two NDCs? The FDA registers this code as 52709-1601-3 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 52709-1601-03. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name RAGWITEK SUBLINGUAL TABLET Ingredient Allergenic Extract-Weed Pollen-Short Ragweed
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $11.749 $352.47 / 30 tablets
Medicaid paysCMS SDUD · 12 mo $11.74 $352.29 / 30 tablets
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Apr 2024 Nov 2024 Nov 2025 Nov 2026 $11.750 $11.054
▲ Up 6% over the last 22 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
52709-1601-03 You're viewing this Main listing 3 BLISTER PACK in 1 CARTON / 10 TABLET in 1 BLISTER PACK Inner NDC 52709-1601-1 · each blister pack (10 tablets) $11.75 / ea $352.47 2014-04-17 — Inactivated by FDA
52709-1601-05 52709-1601-5 1 BLISTER PACK in 1 CARTON / 5 TABLET in 1 BLISTER PACK — — 2014-04-17 — Inactivated by FDA

In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 30-count package — 3 blister pack in 1 carton / 10 tablet in 1 blister pack.
How does this package differ from NDC 52709-1601-05?
Both are RAGWITEK AMBROSIA ARTEMISIIFOLIA POLLEN 12 [Amb'a'1'U]/1 Tablet — the drug itself is identical. This page's package is the 30-count one, while NDC 52709-1601-05 is the 5 tablets package.
What NDC number is used to bill for this package of RAGWITEK AMBROSIA ARTEMISIIFOLIA POLLEN 12 [Amb'a'1'U]/1 Tablet?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Ragwitek 12 [Amb'a'1'U]this 52709-1601-03 ALK-Abello 30 tablets $11.749 — Discontinued —
About this product: this is a biologic. Biologics don't have small-molecule generics — competition comes from FDA-licensed biosimilars (shown above), not generics.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & biosimilar status

🏛️
2014
First FDA approval
Apr 2014
📍
2026
Currently FDA-listed
12 years listed
🔓
·
Biosimilar pathway open
listed protections lapsed 2026
🧬Biologic — competition comes from biosimilars

Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.

🛡️ Latest patent/protection date listed: The latest listed FDA patent/protection lapsed Apr 2026 — those protections no longer apply, though a biosimilar still needs FDA licensure and a manufacturer to market it.
📅 FDA approved Apr 17, 2014

Why the date isn’t exact: Biosimilar timing can change because patents may be challenged, settled, licensed, added or removed, and litigation can move the real date earlier or later.

Patents & exclusivity — FDA Purple Book
Exclusivity RefProduct
2014 2016 2018 2020 2022 2024 2026
Today
LOE
Biologic patent Exclusivity
🏛️Reference-product exclusivity
A flat 12 years of FDA market protection from first licensure. No biosimilar can be licensed before it ends — regardless of patents.
🧪Listed biologic patents
Patents the reference maker lists covering the molecule, formulation, or manufacturing. A biosimilar generally can’t launch until these resolve.
🔁Interchangeability
An interchangeable biosimilar may be substituted at the pharmacy (state laws vary). The first one can earn its own exclusivity period.
🛈 What do these terms mean?
Biologic patent
A patent the reference product’s maker has publicly listed. A biosimilar generally can’t launch until these expire — unless they’re invalidated or resolved in a settlement.
Reference-product exclusivity
A flat 12 years of FDA market protection from the biologic’s first licensure (the BPCIA). No biosimilar can be licensed before it ends, regardless of patents.
Interchangeable exclusivity
The first interchangeable biosimilar can earn a period as the only interchangeable version (pharmacists can substitute it without the prescriber).
Earliest biosimilar (LOE)
The latest of all the dates above — the soonest a biosimilar can realistically reach the market. Litigation and settlements can move it earlier.

Biologics have no small-molecule “generics” — competition comes from FDA-licensed biosimilars, tracked in the FDA Purple Book.

FDA exclusivity
CodeWhat it grantsExpires
RefProductReference-product exclusivity (12-year, BPCIA) — no biosimilar can be licensed before this dateApr 17, 2026
Common questions
Is there a biosimilar for RAGWITEK SUBLINGUAL TABLET?
No FDA-licensed biosimilar is currently listed for this biologic in the FDA Purple Book.
Why do different websites show different biosimilar dates?
Biosimilar availability isn’t based on one single date. Some sources use the reference-product exclusivity, some use the last listed patent, and patent litigation, settlements, and licenses can all change the real-world launch date. This page shows the underlying Purple Book dates so you can see why estimates differ.
Can a biosimilar launch before the last patent expires?
Sometimes. A biosimilar maker may settle with the reference manufacturer or receive a license to launch earlier. In other cases, the last listed protection delays competition.
What does “current Purple Book estimate” mean?
It means we’re using the latest patent and exclusivity dates currently listed in the FDA Purple Book. It is not a guaranteed launch date.
What does “FDA listed” mean?
It means the product appears in the FDA’s official directory. That’s a good sign a product exists for the U.S. market, but on its own it does not confirm a pharmacy can get it today. Where we have recent retail pricing data, we label it “Availability likely” instead.
What does a patent or protection date mean here?
It’s the latest date currently listed in the FDA Purple Book for a patent or exclusivity on the reference biologic. It can affect when a biosimilar becomes widely available — but it is not a guaranteed launch date. Settlements and licenses can move the real date earlier or later.
Built from the FDA Purple Book Patent List (patents the reference-product sponsor has publicly listed under the BPCIA) plus reference-product exclusivity. Biosimilars cannot launch until these clear; patent litigation and settlements can shift the real date. Biologics have no small-molecule generics — competition comes from FDA-licensed biosimilars, not the Orange Book.
Where does this data come from?
Patents and exclusivity from the FDA Purple Book (biologics), refreshed from public FDA data. Biosimilar launch timing is an estimate, not a guarantee.

What it looks like

Color white
ShapeRound
Size12 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 3OWL53L36A
    A natural sugar alcohol derived from seaweed or synthesized in the lab. It's used as a filler to add bulk, a sweetener in sugar-free formulas, and a disintegrant to help tablets break apart in the stomach.
  • UNII 8JC99XGU4W
    Soluble fish skin collagen is a protein derived from fish skin that acts as a binder and thickening agent in medicines. It helps hold ingredients together and gives the product the right texture or consistency.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.

3 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerALK-Abello A S
FDA applicationBLA125478 (BLA)
Labeler code52709
First marketedApr 2014
Product typeStandardized Allergenic
Portfolio3 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🚨 Boxed Warning ~1 min read ▾

WARNING: SEVERE ALLERGIC REACTIONS ● RAGWITEK can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal restriction. ( 5.1 ) ● Do not administer RAGWITEK to patients with severe, unstable or uncontrolled asthma. ( 4 ) ● Observe patients in the office for at least 30 minutes following the initial dose.

( 5.1 ) ● Prescribe auto-injectable epinephrine, instruct and train patients or parents/guardians on its appropriate use, and instruct patients or parents/guardians to seek immediate medical care upon its use. ( 5.2 ) ● RAGWITEK may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction. ( 5.2 ) ● RAGWITEK may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.

( 5.2 ) WARNING: SEVERE ALLERGIC REACTIONS See full prescribing information for complete boxed warning. • RAGWITEK can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal restriction . ( 5.1 ) • Do not administer RAGWITEK to patients with severe, unstable or uncontrolled asthma . ( 4 ) • Observe patients in the office for at least 30 minutes following the initial dose.

( 5.1 ) • Prescribe auto-injectable epinephrine, instruct and train patients or parents/guardians on its appropriate use, and instruct patients or parents/guardians to seek immediate medical care upon its use. ( 5.2 ) • RAGWITEK may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction. ( 5.2 ) • RAGWITEK may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.

( 5.2 )

🎯 Indications and Usage 121 words ▾

1 INDICATIONS AND USAGE RAGWITEK ® is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. RAGWITEK is approved for use in persons 5 through 65 years of age. RAGWITEK is not indicated for the immediate relief of allergic symptoms.

RAGWITEK is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. RAGWITEK is approved for use in persons 5 through 65 years of age. ( 1 )

⏱️ Dosage and Administration ~2 min read ▾

2 DOSAGE AND ADMINISTRATION For sublingual use only. For sublingual use only. One tablet daily.

( 2.1 ) Initiate treatment at least 12 weeks before the expected onset of ragweed pollen season and continue treatment throughout the season. ( 2.2 ) Place the tablet immediately under the tongue. Allow it to remain there until completely dissolved.

Do not swallow for at least 1 minute. ( 2.2 ) Administer the first dose of RAGWITEK under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases. Observe patients in the office for at least 30 minutes following the initial dose.

( 2.2 )

2.1Dos e One RAGWITEK tablet daily. 2. 2 Administration Administer the first dose of RAGWITEK in a healthcare setting under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases.

After receiving the first dose of RAGWITEK, observe the patient for at least 30 minutes to monitor for signs or symptoms of a severe systemic or a severe local allergic reaction. If the patient tolerates the first dose, the patient may take subsequent doses at home. Take the tablet from the blister unit after carefully removing the foil with dry hands.

Place the tablet immediately under the tongue. Allow it to remain there until completely dissolved. Do not swallow for at least 1 minute.

Wash hands after handling the tablet. Do not take the tablet with food or beverage. Food or beverage should not be taken for the following 5 minutes after taking the tablet.

Initiate treatment at least 12 weeks before the expected onset of ragweed pollen season and continue treatment throughout the season. The safety and efficacy of initiating treatment in season have not been established. Data regarding the safety of restarting treatment after missing a dose of RAGWITEK are limited.

In the clinical trials, treatment interruptions for up to seven days were allowed. Prescribe auto-injectable epinephrine to patients prescribed RAGWITEK and instruct them (or their parents/guardians) in the proper use of auto-injectable epinephrine [see Warnings and Precautions ( 5.2 )] .

💊 Dosage Forms and Strengths 42 words ▾

3 DOSAGE FORMS AND STRENGTHS RAGWITEK is available as 12 Amb a 1-Unit (Amb a 1-U) tablets that are white to off-white, circular with a debossed double hexagon on one side. Tablet, 12 Amb a 1-Unit (Amb a 1-U) ( 3 )

⛔ Contraindications 109 words ▾

4 CONTRAINDICATIONS RAGWITEK is contraindicated in patients with: Severe, unstable or uncontrolled asthma A history of any severe systemic allergic reaction A history of any severe local reaction after taking any sublingual allergen immunotherapy A history of eosinophilic esophagitis Hypersensitivity to any of the inactive ingredients [gelatin, mannitol, and sodium hydroxide] contained in this product [see Description ( 11 )]. Severe, unstable or uncontrolled asthma. ( 4 ) History of any severe systemic allergic reaction or any severe local reaction to sublingual allergen immunotherapy.

( 4 ) A history of eosinophilic esophagitis. ( 4 ) Hypersensitivity to any of the inactive ingredients contained in this product. ( 4 )

⚠️ Warnings and Cautions ~3 min read ▾

5 WARNINGS AND PRECAUTIONS Inform patients or parents/guardians of the signs and symptoms of serious allergic reactions and instruct them to seek immediate medical care and discontinue therapy should any of these occur. ( 5.1 ) In case of oral inflammation or wounds, stop treatment with RAGWITEK to allow complete healing of the oral cavity. ( 5. 7 )

5.1Severe Allergic Reactions RAGWITEK can cause systemic allergic reactions including anaphylaxis which may be life-threatening. In addition, RAGWITEK can cause severe local reactions, including laryngopharyngeal swelling, which can compromise breathing and be life-threatening. Allergic reactions may require treatment with epinephrine.

Prescribe auto-injectable epinephrine to patients receiving RAGWITEK. Instruct patients or parents/guardians to recognize the signs and symptoms of a severe allergic reaction and in the proper use of auto-injectable epinephrine. Instruct patients or parents/guardians to seek immediate medical care and to stop treatment with RAGWITEK upon use of auto-injectable epinephrine [see Patient Counseling Information ( 17 )] .

See Prescribing Information for epinephrine for complete information. RAGWITEK may not be suitable for patients with certain medical conditions that may reduce the ability to survive a serious allergic reaction or that may increase the risk of adverse reactions after epinephrine administration. Examples of these medical conditions include but are not limited to: markedly compromised lung function (either chronic or acute); severe mast cell disorder; or cardiovascular disease including unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension.

In addition, RAGWITEK may not be suitable for patients who are taking medications that can potentiate or inhibit the effects of epinephrine (see Prescribing Information for epinephrine for information on drug interactions). Administer the initial dose of RAGWITEK in a healthcare setting under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases and prepared to manage a life-threatening systemic or local allergic reaction. Observe patients in the office for at least 30 minutes following the initial dose of RAGWITEK.

5. 2 Upper Airway Compromise RAGWITEK can cause local reactions in the mouth or throat that could compromise the upper airway [see Adverse Reactions ( 6.1 )] . Consider discontinuation of RAGWITEK in patients who experience persistent and escalating adverse reactions in the mouth or throat.

5. 3 Eosinophilic Esophagitis Eosinophilic esophagitis has been reported in association with sublingual tablet immunotherapy [see Contraindications ( 4 )] . Discontinue RAGWITEK and consider a diagnosis of eosinophilic esophagitis in patients who experience severe or persistent gastro-esophageal symptoms including dysphagia or chest pain.

5. 4 Asthma Subjects with asthma who participated in clinical trials had asthma of a severity that required, at most, a daily medium dose of an inhaled corticosteroid. RAGWITEK has not been studied in subjects with severe asthma.

Withhold immunotherapy with RAGWITEK if the patient is experiencing an acute asthma exacerbation. Reevaluate patients who have recurrent asthma exacerbations and consider discontinuation of RAGWITEK. 5.

5 Concomitant Allergen Immunotherapy RAGWITEK has not been studied in subjects who are receiving concomitant allergen immunotherapy. Concomitant dosing with other allergen immunotherapy may increase the likelihood of local or systemic adverse reactions to either subcutaneous or sublingual allergen immunotherapy. 5.

6 Oral Inflammation Stop treatment with RAGWITEK to allow complete healing of the oral cavity in patients with oral inflammation (e.g., oral lichen planus, mouth ulcers, or thrush) or oral wounds, such as those following oral surgery or dental extraction.

🤒 Adverse Reactions ~3 min read ▾

6 ADVERSE REACTIONS Adverse reactions reported in ≥5% of adults were: throat irritation, oral pruritus, ear pruritus, oral paresthesia, mouth edema, and tongue pruritus. Adverse reactions reported in ≥5% of children and adolescents 5 through 17 years of age were: throat irritation, oral pruritus, ear pruritus, lip swelling, glossodynia, nausea, oral pain, pharyngeal edema, swollen tongue, abdominal pain upper, stomatitis, and enlarged uvula. Adverse reactions reported in ≥5% of adults were: throat irritation, oral pruritus, ear pruritus, oral paresthesia, mouth edema, and tongue pruritus.

Adverse reactions reported in ≥5% of children and adolescents 5 through 17 years of age were: throat irritation, oral pruritus, ear pruritus, lip swelling, glossodynia, nausea, oral pain, pharyngeal edema, swollen tongue, abdominal pain upper, stomatitis, and enlarged uvula. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact ALK-Abelló Inc., a subsidiary of ALK-Abelló A/S, at 1-855-216-6497 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice . Adults In 4 placebo-controlled clinical trials, 1057 subjects 18 years of age and older with short ragweed pollen-induced rhinitis, with or without conjunctivitis, received at least one dose of RAGWITEK, of whom 327 (31%) completed at least 12 weeks of therapy.

Of the subjects treated with RAGWITEK, 52% were male, 25% had mild asthma, and 82% were sensitized to other allergens in addition to ragweed pollen. The subject population was 83% White, 12% African American, and 2% Asian. Subject demographics in placebo-treated subjects were similar to the active group.

The pooled analysis includes safety data from two 28-day safety studies and safety data from the first 28 days of two 52-week safety and efficacy studies. Adverse reactions reported in ≥1% of subjects in the 28-day pooled analysis treated with RAGWITEK are shown in Table 1. The most common adverse reactions reported in subjects treated with RAGWITEK were throat irritation (16.6% vs 3.3% placebo), oral pruritus (10.9% vs 2.0%), ear pruritus (10.4% vs 1.1%), and oral paresthesia (10.0% vs 4.0%).

The percentage of subjects who discontinued from the clinical trials because of an adverse reaction while exposed to RAGWITEK or placebo was 4.4% and 0.8%, respectively. The most common adverse reactions that led to study discontinuation in subjects who were exposed to RAGWITEK were mouth edema, swollen tongue, and dysphagia. One subject (1/1057; 0.1%) who received RAGWITEK experienced a treatment-related severe systemic allergic reaction that led to discontinuation of RAGWITEK.

The subject had local reactions starting on Day 1 of treatment with RAGWITEK. On Day 6 symptoms progressed and included swelling of the throat, dyspnea, nausea, and lightheadedness. The subject fully recovered after treatment with epinephrine (self-administered), antihistamines, and oral corticosteroids.

Table 1: Adverse Reactions Reported in ≥1% of Adults Treated with RAGWITEK or Placebo (28-day pooled analysis) Adverse Reaction RAGWITEK (N=1057) Placebo (N=757) Ear and Labyrinth Disorders Ear pruritus 10.4% 1.1% Respiratory, Thoracic and Mediastinal Disorders Throat irritation Oropharyngeal pain Throat tightness 16.6% 1.5% 1.3% 3.3% 0.7% 0.5% Gastrointestinal Disorders Oral pruritus Paresthesia oral Mouth edema Tongue pruritus Lip swelling Swollen tongue Lip pruritus Dry mouth Tongue edema Nausea Palatal edema Dysphagia 10.9% 10.0% 6.1% 5.1% 3.0% 2.9% 1.5% 1.4% 1.3% 1.1% 1.1% 1.0% 2.0% 4.0% 0.5% 0.5% 0.4% 0.5% 0.1% 0.7% 0.5% 0.3% 0% 0% Skin and Subcutaneous Tissue Disorders Pruritus 1.8% 1.3% General Disorders and Administration Site C onditions Chest discomfort 1.0% 0% * 1036 subjec… [Excerpted — this section continues on DailyMed.]

👥 Use in Specific Populations ~1 min read ▾

8 USE IN SPECIFIC POPULATIONS

8.1Pregnancy Risk Summary All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Available human data do not establish the presence or absence of RAGWITEK-associated risks during pregnancy.

In an embryo/fetal developmental toxicity study, RAGWITEK subcutaneously administered to mice during gestation at doses up to approximately 3 times the human sublingual dose did not reveal adverse developmental outcomes in fetuses (see

8.1Data) . Data Animal Data In a developmental toxicity study, the effect of RAGWITEK on embryo/fetal development was evaluated in mice. Animals were administered RAGWITEK subcutaneously daily from day 6 to day 15 of the gestation period at doses approximately 1 to 3 times the human sublingual dose of 12 Amb a 1-U.

There were no RAGWITEK-related post-implantation losses, fetal malformations or variations. 8. 2 Lactation Risk Summary It is not known whether RAGWITEK is excreted in human milk.

Data are not available to assess the effects of RAGWITEK on the breastfed child or on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for RAGWITEK and any potential adverse effects on the breastfed child from RAGWITEK or from the underlying maternal condition.

8.4Pediatric Use Efficacy and safety of RAGWITEK have been established in children and adolescents 5 through 17 years of age. The efficacy and safety in pediatric patients below 5 years of age have not been established.

8.5Geriatric Use RAGWITEK is not approved for use in patients over 65 years of age because safety and efficacy have not been established.

🤰 Pregnancy 157 words ▾

8.1Pregnancy Risk Summary All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Available human data do not establish the presence or absence of RAGWITEK-associated risks during pregnancy.

In an embryo/fetal developmental toxicity study, RAGWITEK subcutaneously administered to mice during gestation at doses up to approximately 3 times the human sublingual dose did not reveal adverse developmental outcomes in fetuses (see

8.1Data) . Data Animal Data In a developmental toxicity study, the effect of RAGWITEK on embryo/fetal development was evaluated in mice. Animals were administered RAGWITEK subcutaneously daily from day 6 to day 15 of the gestation period at doses approximately 1 to 3 times the human sublingual dose of 12 Amb a 1-U. There were no RAGWITEK-related post-implantation losses, fetal malformations or variations.

🧒 Pediatric Use 37 words ▾

8.4Pediatric Use Efficacy and safety of RAGWITEK have been established in children and adolescents 5 through 17 years of age. The efficacy and safety in pediatric patients below 5 years of age have not been established.

🧓 Geriatric Use 24 words ▾

8.5Geriatric Use RAGWITEK is not approved for use in patients over 65 years of age because safety and efficacy have not been established.

🧬 Clinical Pharmacology 18 words ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action The precise mechanisms of action of allergen immunotherapy are not known.

🧬 Mechanism of Action 15 words ▾

12.1Mechanism of Action The precise mechanisms of action of allergen immunotherapy are not known.

📦 How Supplied / Storage and Handling 73 words ▾

16 HOW SUPPLIED/STORAGE AND HANDLING RAGWITEK 12 Amb a 1-U tablets are white to off-white, circular sublingual tablets with a debossed double hexagon on one side. RAGWITEK is supplied as follows: 3 blister packages of 10 tablets (30 tablets total). NDC 52709-1601-3 Store at controlled room temperature, 20ºC to 25ºC (68ºF to 77ºF); excursions permitted between 15ºC to 30ºC (59ºF to 86ºF). Store in the original package until use to protect from moisture.

📋 Description 54 words ▾

11 DESCRIPTION RAGWITEK tablets contain pollen allergen extract from Short Ragweed ( Ambrosia artemisiifolia ). RAGWITEK is a sublingual tablet that dissolves within 10 seconds. RAGWITEK is available as a tablet of 12 Amb a 1-U of short ragweed pollen allergen extract. Inactive ingredients: gelatin NF (fish source), mannitol USP, and sodium hydroxide NF.

💬 Information for Patients ~2 min read ▾

17 PATIENT COUNSELING INFORMATION Advise patients or parents/guardians to read the FDA-approved patient labeling ( Medication Guide ) and to keep RAGWITEK and all medicines out of the reach of children. Severe Allergic Reactions Advise patients or parents/guardians that RAGWITEK may cause life-threatening systemic or local allergic reactions, including anaphylaxis. Educate patients or parents/guardians about the signs and symptoms of these allergic reactions [see Warnings and Precautions ( 5.1 )] .

The signs and symptoms of a severe allergic reaction may include: syncope, dizziness, hypotension, tachycardia, dyspnea, wheezing, bronchospasm, chest discomfort, cough, abdominal pain, vomiting, diarrhea, rash, pruritus, flushing, and urticaria. Ensure that patients (or their parents/guardians) have auto-injectable epinephrine and instruct patients or parents/guardians in its proper use. Instruct patients (or their parents/guardians) who experience a severe allergic reaction to seek immediate medical care, discontinue RAGWITEK, and resume treatment only when advised by a physician to do so [ s ee Warnings and Precautions ( 5.1 )] .

Advise patients or parents/guardians to read the patient information for epinephrine. Inform patients or parents/guardians that the first dose of RAGWITEK must be administered in a healthcare setting under the supervision of a physician and that they will be monitored for at least 30 minutes to watch for signs and symptoms of life-threatening systemic or local allergic reaction [see Warnings and Precautions ( 5.1 )] . Because of the risk of upper airway compromise, instruct patients (or their parents/guardians) with persistent and escalating adverse reactions in the mouth or throat to discontinue RAGWITEK and to contact their healthcare professional [ s ee Warnings and Precautions ( 5.2 )] .

Because of the risk of eosinophilic esophagitis, instruct patients (or their parents/guardians) with severe or persistent symptoms of esophagitis to discontinue RAGWITEK and to contact their healthcare professional [ s ee Warnings and Precautions ( 5.3 )] . Asthma Instruct patients (or their parents/guardians) with asthma that if they have difficulty breathing or if their asthma becomes difficult to control, they should stop taking RAGWITEK and contact their healthcare professional immediately [see Warnings and Precautions ( 5.4 )] .

Administration Instructions Instruct patients (or their parents/guardians) to carefully remove the foil from the blister unit with dry hands and then take the sublingual tablet immediately by placing it under the tongue where it will dissolve. Also instruct patients (or their parents/guardians) to wash their hands after handling the tablet, and to avoid food or beverages for 5 minutes after taking the tablet [ s ee Dosage and Administration ( 2.2 )] . Manufactured for: ALK-Abelló A/S ALK-Abelló A/S, Bøge Allé 6-8, DK-2970 Hørsholm, Denmark U.S.

License No. 1292 Manufactured by: Catalent Pharma Solutions Limited, Blagrove, Swindon, Wiltshire, SN5 8RU UK Copyright © 2022 ALK-Abelló A/S. All rights reserved.

💬 Medication Guide ~3 min read ▾

MEDICATION GUIDE RAGWITEK ® (RAG-wi-tek) (Short Ragweed Pollen Allergen Extract) Carefully read this Medication Guide before you or your child start taking RAGWITEK ® and each time you get a refill. This Medication Guide does not take the place of talking with your doctor about your medical condition or treatment. Talk with your doctor or pharmacist if there is something you do not understand or if you want to learn more about RAGWITEK.

What is the Most Important Information I Should Know about RAGWITEK? RAGWITEK can cause severe allergic reactions that may be life-threatening. Stop taking RAGWITEK and get medical treatment right away if you or your child have any of the following symptoms after taking RAGWITEK: Trouble breathing Throat tightness or swelling Trouble swallowing or speaking Dizziness or fainting Rapid or weak heartbeat Severe stomach cramps or pain, vomiting, or diarrhea Severe flushing or itching of the skin For home administration of RAGWITEK, your doctor will prescribe auto-injectable epinephrine, a medicine you can inject if you or your child have a severe allergic reaction after taking RAGWITEK.

Your doctor will train and instruct you on the proper use of auto-injectable epinephrine. Talk to your doctor or read the epinephrine patient information if you have any questions about the use of auto-injectable epinephrine. What is RAGWITEK ?

RAGWITEK is a prescription medicine used for sublingual (under the tongue) immunotherapy to treat ragweed pollen allergies that can cause sneezing, runny or itchy nose, stuffy or congested nose, or itchy and watery eyes. RAGWITEK may be prescribed for persons 5 through 65 years of age who are allergic to ragweed pollen. RAGWITEK is taken for about 12 weeks before ragweed pollen season and throughout ragweed pollen season.

RAGWITEK is NOT a medication that gives immediate relief for symptoms of ragweed allergy. RAGWITEK is not approved for use in children younger than 5 years of age or in adults older than 65 years of age. Who Should Not Take RAGWITEK?

You or your child should not take RAGWITEK if: You or your child have severe, unstable or uncontrolled asthma You or your child had a severe allergic reaction in the past that included any of these symptoms: ○ Trouble breathing ○ Dizziness or fainting ○ Rapid or weak heartbeat You or your child have ever had difficulty with breathing due to swelling of the throat or upper airway after using any sublingual immunotherapy before. You or your child have ever been diagnosed with eosinophilic esophagitis. You or your child are allergic to any of the inactive ingredients contained in RAGWITEK.

The inactive ingredients contained in RAGWITEK are: gelatin, mannitol, and sodium hydroxide. What Should I Tell My Doctor Before Taking RAGWITEK? Your doctor may decide that RAGWITEK is not the best treatment if: You or your child have asthma, depending on how severe it is.

You or your child suffer from lung disease such as chronic obstructive pulmonary disease (COPD) You or your child suffer from heart disease such as coronary artery disease, an irregular heart rhythm, or you have hypertension that is not well controlled. You or your daughter are pregnant, plan to become pregnant during the time you will be taking RAGWITEK, or are breast-feeding. You or your child are unable or unwilling to administer auto-injectable epinephrine to treat a severe allergic reaction to RAGWITEK.

You or your child are taking certain medicines that enhance the likelihood of a severe reaction, or interfere with the treatment of a severe reaction. These medicines include: ○ beta blockers and alpha-blockers (prescribed for high blood pressure) ○ cardiac glycosides (prescribed for heart failure or problems with heart rhythm) ○ diuretics (prescribed for heart conditions and high blood pressure) ○ ergot alkaloids (prescribed for migraine headache) ○ monoamine oxidase inhibitors or tricyclic antidepressants (prescribed for depression) ○ thyroid hormone (prescribed for low… [Excerpted — this section continues on DailyMed.]

🔬 Clinical Studies ~3 min read ▾

14 CLINICAL STUDIES Adults The efficacy of RAGWITEK in the treatment of ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, was investigated in two double-blind, placebo-controlled clinical trials in adults 18 through 50 years of age. Subjects received RAGWITEK or placebo for approximately 12 weeks prior to the start of the ragweed pollen season and throughout the ragweed pollen season. The subject population was 86% White, 9% African American, and 3% Asian.

The subject population was almost equally divided between males and females. Overall, the mean age of subjects was 36 years. Subjects with asthma who participated in clinical trials had asthma of a severity that required, at most, a daily low dose of an inhaled corticosteroid.

Approximately 16% of subjects had mild asthma at baseline. Efficacy was established by self-reporting of rhinoconjunctivitis daily symptom scores (DSS) and daily medication scores (DMS). Daily rhinoconjunctivitis symptoms included four nasal symptoms (runny nose, stuffy nose, sneezing, and itchy nose), and two ocular symptoms (gritty/itchy eyes and watery eyes).

The rhinoconjunctivitis symptoms were measured on a scale of 0 (none) to 3 (severe). Subjects in clinical trials were allowed to take symptom-relieving medications (including systemic and topical antihistamines, and topical and oral corticosteroids) as needed. The daily medication score measured the use of standard open-label allergy medications.

Predefined values were assigned to each class of medication. Generally, systemic and topical antihistamines were given the lowest score, topical steroids an intermediate score, and oral corticosteroids the highest score. The sums of the DSS and DMS were combined into the Total Combined Score (TCS) which was averaged over the peak ragweed pollen season.

Also, in each study, the average TCS over the entire ragweed season was assessed. Other endpoints in both studies included the average DSS during the peak and entire ragweed season, and the average DMS during the peak ragweed season. Trial 1 The first study was a placebo-controlled trial which evaluated subjects 18 through 50 years of age comparing RAGWITEK (n=187) and placebo (n=188) administered as a sublingual tablet daily.

In this trial, approximately 22% of subjects had mild asthma and 85% were sensitized to other allergens in addition to short ragweed. Subjects with asthma who participated in this trial had asthma of a severity that required, at most, a daily low dose of an inhaled corticosteroid. Subjects with a clinical history of symptomatic allergies to non-short ragweed pollen allergens that required treatment during the ragweed pollen season were excluded from the trial.

The subject population was 78% White, 12% African American, and 8% Asian, and almost equally divided between males and females. The mean age of subjects in this study was 35.4 years. The two treatment groups were balanced with regard to baseline characteristics.

The results of this study are shown in Table 4. Trial 2 The second study was a placebo-controlled trial which evaluated subjects 18 through 50 years of age comparing RAGWITEK (n=194) and placebo (n=198) administered as a sublingual tablet daily. Approximately 17% of subjects had mild asthma and 78% were sensitized to other allergens in addition to short ragweed.

Subjects with asthma who participated in this trial had asthma of a severity that required, at most, a daily low dose of an inhaled corticosteroid. Subjects with a clinical history of symptomatic allergies to non-short ragweed pollen allergens that required treatment during the ragweed pollen season were excluded from the trial. The subject population was 88% White, 8.9% African American, 2% Asian, and almost equally divided between males and females.

The mean age of subjects in this study was 36.4 years. The two treatment groups were balanced with regard to baseline characteristics. The results of this study are shown in Table 5.

A dec… [Excerpted — this section continues on DailyMed.]

🧪 Nonclinical Toxicology 62 words ▾

13 NONCLINICAL TOXICOLOGY

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility No studies have been performed in animals to evaluate the carcinogenic potential of RAGWITEK . There were no positive findings in a combined in vivo Comet and micronucleus assay in rats using Short Ragweed ( Ambrosia artemisiifolia ) pollen allergen extract. Fertility studies have not been performed with Short Ragweed pollen allergen extract.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 59 words ▾

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility No studies have been performed in animals to evaluate the carcinogenic potential of RAGWITEK . There were no positive findings in a combined in vivo Comet and micronucleus assay in rats using Short Ragweed ( Ambrosia artemisiifolia ) pollen allergen extract. Fertility studies have not been performed with Short Ragweed pollen allergen extract.

📄 Recent Major Changes 7 words ▾

Indications and Usage ( 1 ) 04/2021

📄 Package Label / Principal Display Panel 145 words ▾

PRINCIPAL DISPLAY PANEL NDC 52709-1601-3 This carton contains 30 sublingual tablets in three 10-Tablet blister cards Short R agweed Pollen Allergen Extract, Ragwitek ® Tablet for sublingual use 12 Amb a 1-U For Persons 5 through 65 Years of Age Each Ragwitek tablet contains 12 Amb a 1-U of short ragweed pollen allergen extract. Dispense the enclosed Medication Guide to the patient. Keep this and all drugs out of the reach of children.

Rx only NDC 52709-1601-3 This carton contains 30 sublingual tablets in three 10-Tablet blister cards Short Ragweed Pollen Allergen Extract, Ragwitek® Tablet for sublingual use 12 Amb a 1-U For Persons 5 through 65 Years of Age Each Ragwitek tablet contains 12 Amb a 1-U of short ragweed pollen allergen extract. Dispense the enclosed Medication Guide to the patient. Keep this and all drugs out of the reach of children.

Rx only

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
132
Units reimbursed last 4 qtrs
4.1K
Gross reimbursed last 4 qtrs
$47.9K
Avg / prescription
$362.96
Avg / unit
$11.7429
Latest quarter Q1 2026
13Rx
Medicaid pays / ea
$11.7429
gross reimbursed
vs
NADAC / ea
$11.7490
acquisition cost
=
Spread
−$0.0061
+0% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
92% FFS
Fee-for-service · 121 Rx Managed care · 11 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: 330 units · 3.3 per 100k residents MI New York: 1,620 units · 8.3 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: no data reported OH Pennsylvania: no data reported PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: 1,470 units · 3.8 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: 660 units · 10.7 per 100k residents MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
3.310.7
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Missouri 10.7 /100k
2 New York 8.3 /100k
3 California 3.8 /100k
4 Michigan 3.3 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
5 tablets52709-1601-05 No Medicaid data
Drug total (last 4 qtrs): 365 Rx · 11,223 units · $130,027 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Ragwitek — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Ragwitek. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$25.9K
Claims incl. refills
59
Beneficiaries
38
Spend / beneficiary
$681.04
Spend / claim
$438.64
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

No longer marketed (per FDA listing data)
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

What does the discontinued status mean for this NDC?
The labeler reported a marketing end date (or the listing was delisted), so this specific package is no longer actively marketed. Remaining stock may still be dispensed for a time, and the NDC stays valid for historical records and claims — but data feeds (pricing, labeling) typically stop updating for it. Other package sizes or other manufacturers' versions of the same medication may still be marketed — see the equivalents section where available.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 5 tablets (52709-1601-05). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
ALK-Abello A S is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.